Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus

Journal of the American Society of Nephrology

Volumn 22, Issue 4, 2011, Pages 782-790

  Fenske, Wiebke ^a   Wanner, Christoph ^a   Allolio, Bruno ^a   Drechsler, Christiane ^a   Blouin, Katja ^a   Lilienthal, Jürgen ^b   Krane, Vera ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Datamap GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; COPEPTIN; GLYCOPEPTIDE; PLACEBO; UNCLASSIFIED DRUG; VASOPRESSIN;

AGED; ARTICLE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART INFARCTION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STROKE; SUDDEN DEATH;

EID: 79953300299     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2010070691     Document Type: Article

References (44)

1. Stoiser B, Mortl D, Hulsmann M, Berger R, Struck J, Morgenthaler NG, Bergmann A, Pacher R: Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 36: 771-778, 2006 (Pubitemid 44569965)
2. Neuhold S, Huelsmann M, Strunk G, Struck J, Adlbrecht C, Gouya G, Elhenicky M, Pacher R: Prognostic value of emerging neurohormones in chronic heart failure during optimization of heart failure-specific therapy. Clin Chem 56: 121-126, 2010
3. Morgenthaler NG, Struck J, Alonso C, Bergmann A: Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52: 112-119, 2006 (Pubitemid 43032474)
4. US Renal Data System: USRDS 2008 Annual Data Report, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2008
5. Teitelbaum I, McGuinness S: Vasopressin resistance in chronic renal failure. Evidence for the role of decreased V2 receptor mRNA. J Clin Invest 96: 378-385, 1995
6. Tannen RL, Regal EM, Dunn MJ, Schrier RW: Vasopressin-resistant hyposthenuria in advanced chronic renal disease. N Engl J Med 280: 1135-1141, 1969
7. Fine LG, Schlondorff D, Trizna W, Gilbert RM, Bricker NS: Functional profile of the isolated uremic nephron. Impaired water permeability and adenylate cyclase responsiveness of the cortical collecting tubule to vasopressin. J Clin Invest 61: 1519-1527, 1978 (Pubitemid 8361878)
8. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005 (Pubitemid 41058323)
9. Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler NG, Bergmann A, Moertl D, Berger R, Pacher R: Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: Prediction of death at different stages of the disease. J Am Coll Cardiol 52: 266-272, 2008 (Pubitemid 351957847)
10. Kelly D, Squire IB, Khan SQ, Quinn P, Struck J, Morgenthaler NG, Davies JE, Ng LL: C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. J Card Fail 14: 739-745, 2008
11. Chai SB, Hui YM, Li XM, Xiao Y, Tang CS: Plasma levels of copeptin in patients with coronary heart disease. Heart Vessels 24: 79-83, 2009
12. Staub D, Morgenthaler NG, Buser C, Breidthardt T, Potocki M, Noveanu M, Reichlin T, Bergmann A, Mueller C: Use of copeptin in the detection of myocardial ischemia. Clin Chim Acta 399: 69-73, 2009
13. Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, Bingisser R, Muller K, Meckel S, Gass A, Kappos L, Steck AJ, Engelter ST, Muller B, Christ-Crain M: Copeptin: A novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 66: 799-808, 2009
14. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ: Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet 367: 1747-1757, 2006
15. Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB, Kerr PG, Young EW, Robinson BM. Atrial fibrillation in hemodialysis patients: Clinical features and associations with anticoagulant therapy. Kidney Int 12: 1098-1106, 2010
16. Winkler K, Wanner C, Drechsler C, Lilienthal J, Marz W, Krane V: Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients. Eur Heart J 29: 2092-2099, 2008
17. Krane V, Winkler K, Drechsler C, Lilienthal J, Marz W, Wanner C: Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int 74: 1461-1467, 2008
18. Martin de Aguilera E, Vila JM, Irurzun A, Martinez MC, Martinez Cuesta MA, Lluch S: Endothelium-independent contractions of human cerebral arteries in response to vasopressin. Stroke 21: 1689-1693, 2009
19. Spatz M, Stanimirovic D, Bacic F, Uematsu S, McCarron RM: Vasoconstrictive peptides induce endothelin-1 and prostanoids in human cerebromicrovascular endothelium. Am J Physiol 266: 654-660, 1994
20. Lam TI, Wise PM, O'Donnell ME: Cerebral microvascular endothelial cell Na/H exchange: Evidence for the presence of NHE1 and NHE2 isoforms and regulation by arginine vasopressin. Am J Physiol Cell Physiol 297: 278-289, 2009
21. Rosenberg GA, Scremin O, Estrada E, Kyner WT: Arginine vasopressin V1-antagonist and atrial natriuretic peptide reduce hemorrhagic brain edema in rats. Stroke 23: 1767-1773, 1992
22. Holmberg L, Nilsson IM, Borge L, Gunnarsson M, Sjorin E: Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in Type IIB von Willebrand's disease. N Engl J Med 309: 816-821, 1983 (Pubitemid 13005034)
23. Drechsler C, Krane V, Ritz E, Marz W, Wanner C: Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation 120: 2421-2428, 2009
24. Ritz E, Wanner C: The challenge of sudden death in dialysis patients. Clin J Am Soc Nephrol 3: 920-929, 2008
25. Goldsmith SR: Vasopressin as vasopressor. Am J Med 82: 1213-1219, 1982
26. Fukuzawa J, Haneda T, Kikuchi K: Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mol Cell Biochem 195: 93-98, 1999 (Pubitemid 29259773)
27. Sauter A, Machura K, Neubauer B, Kurtz A, Wagner C: Development of renin expression in the mouse kidney. Kidney Int 73: 43-51, 2008 (Pubitemid 350273634)
28. Maturi MF, Martin SE, Markle D, Maxwell M, Burruss CR, Speir E, Greene R, Ro YM, Vitale D, Green MV, Goldstein SR, Bacharach SL, Patterson RE: Coronary vasoconstriction induced by vasopressin. Production of myocardial ischemia in dogs by constriction of nondiseased small vessels. Circulation 83: 2111-2121, 1991
29. Funder JW: RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 93: 121-125, 2005
30. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, Kato T, Izawa H, Murohara T, Yokota M: Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 47: 656-664, 2006 (Pubitemid 43740235)
31. Guder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G, Angermann CE, Stork S: Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 115: 1754-1761, 2007 (Pubitemid 46648612)
32. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717, 1999 (Pubitemid 29407370)
33. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321, 2003 (Pubitemid 36384098)
34. Voors AA, von Haehling S, Anker SD, Hillege HL, Struck J, Hartmann O, Bergmann A, Squire I, van Veldhuisen DJ, Dickstein K: C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: Results from the OPTIMAAL study. Eur Heart J 30: 1187-1194, 2009
35. Masson S, Latini R, Carbonieri E, Moretti L, Rossi MG, Ciricugno S, Milani V, Marchioli R, Struck J, Bergmann A, Maggioni AP, Tognoni G, Tavazzi L: The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: Data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail 12: 338-344, 2010
36. Khan SQ, Dhillon OS, O'Brien RJ, Struck J, Quinn PA, Morgenthaler NG, Squire IB, Davies JE, Bergmann A, Ng LL: C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 115: 2103-2110, 2007 (Pubitemid 46659061)
37. Gegenhuber A, Struck J, Dieplinger B, Poelz W, Pacher R, Morgenthaler NG, Bergmann A, Haltmayer M, Mueller T: Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 13: 42-49, 2007 (Pubitemid 46343794)
38. Meijer E, Bakker SJ, Halbesma N, de Jong PE, Struck J, Gansevoort RT: Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int 77: 29-36, 2009
39. Meijer E, Bakker SJ, de Jong PE, Homan van der Heide JJ, van Son WJ, Struck J, Lems SP, Gansevoort RT: Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation 88: 561-567, 2009
40. Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL: Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) 116: 257-263, 2009
41. Maier C, Clodi M, Neuhold S, Resl M, Elhenicky M, Prager R, Moertl D, Strunk G, Luger A, Struck J, Pacher R, Hulsmann M: Endothelial markers may link kidney function to cardiovascular events in type 2 diabetes. Diabetes Care 32: 1890-1895, 2009
42. Inaba K, Umeda Y, Yamane Y, Urakami M, Nagata T, Inada M: Platelet vasopressin receptor in patients with chronic renal failure. Nippon Jinzo Gakkai Shi 31: 1079-1084, 1989
43. Decaux G, Soupart A, Vassart G: Non-peptide arginine-vasopressin antagonists: The vaptans. Lancet 371: 1624-1632, 2008 (Pubitemid 351626846)
44. Krane V, Heinrich F, Meesmann M, Olschewski M, Lilienthal J, Angermann C, Stork S, Bauersachs J, Wanner C, Frantz S: Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clin J Am Soc Nephrol 4: 394-400, 2009